Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Stock Information for Bolt Biotherapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Pacira Appoints Frank D. Lee as Chief Executive Officer
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual Meeting
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.